Tern Plc portfolio company Konektio fundraise as the business continues to make progress

IoT

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage disruptive Internet of Things (IoT) technology businesses, has announced that its portfolio company, InVMA Limited, which trades as Konektio has completed a £0.3m equity fundraise. Tern has invested £0.1m in the Konektio Fundraise, with the remainder provided by Konektio’s other institutional investors Mercia and Foresight. Tern has also converted £0.5m of convertible loan notes in Konektio.

Prior to the Konektio Fundraise, Tern had a holding of 36.8% in Konektio and as at 30 June 2022, the date of Tern’s last published book valuation, this holding had an unaudited book valuation of £2.2m.  Since 30 June 2022, Tern, alongside others, has provided funding to Konektio by subscribing for Convertible Loan Notes, which bore annual interest of 8%, and the entire principal amount and accrued interest have now converted, in line with the Convertible Loan Notes’ terms, into new equity in Konektio at a discount of between 10% and 20% to the Konektio Fundraise price.  Post the Konektio Fundraise, Tern’s holding in Konektio has increased to 39.9% (before any dilution on exercise of any Konektio employee share options) and Tern’s holding now has an unaudited book valuation, at the Konektio Fundraise price, of £1.0m. 

Including its participation in the Konektio Fundraise and the Convertible Loan Notes, Tern has, to date, invested approximately £2.2m in Konektio.  The Konektio Fundraise values Konektio in total at approximately £3m on a post-money basis.

Commenting Al Sisto, CEO of Tern, said:

“The macroeconomic backdrop remains difficult, with high inflation and high interest rates weighing heavily on the technology ecosystem.  The landscape for technology company valuations has therefore deteriorated dramatically within the last year.  Whilst I am encouraged by the support of our co-investors in working to keep AssetMinder at the forefront of its markets through this modest funding round, I am disappointed to have to report a 55% decline in the fair value of our investment in Konektio.  In our view, this fails to reflect the strategic progress that has been made within the business and which we expect to continue over coming months.

“Our direct and hands-on support of Konektio is delivering results, and the business continues to make progress.  We are encouraged by the market acceptance of the new release of AssetMinder and the increase in Annual Recurring Revenue (ARR) at the company.  The investor group are keen on continuing this progress and look forward to the ability of the business to become self-supporting.“

Konektio

Konektio provides an Industrial IoT Software as a Service (SaaS) platform to Original Equipment Manufacturers (OEMs) and aftermarket customers, as well as the connected product market.  The software enables remote asset monitoring and management to drive productivity improvements.  Konektio’s primary product, AssetMinder, is machine agnostic and allows manufacturers to diagnose issues and proactively prescribe services plans, ultimately reducing downtime and improving operational efficiency.  According to the latest filed financial statements for Konektio, for the 12 month period ended 31 December 2021, the business recorded an increase in retained unaudited losses of £0.4m and at that date had unaudited net assets of approximately £1.8m.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search